Stability Indicating Liquid Chromatographic Method for the Determination of Fenofibrate and its Application to Kinetic Studies



  • K. Srinivasa Rao
  • Keshar N K
  • N Jena
  • M.E.B Rao
  • A K Patnaik


A stability-indicating LC assay method was developed for the quantitative determination of fenofibrate (FFB) in pharmaceutical dosage form in the presence of its degradation products and kinetic determinations were evaluated in acidic, alkaline and peroxide degradation conditions. Chromatographic separation was achieved by use of Zorbax C18 column (250 × 4.0 mm, 5 μm). The mobile phase was established by mixing phosphate buffer (pH adjusted 3 with phosphoric acid) and acetonitrile (30:70 v/v). FFB degraded in acidic, alkaline and hydrogen peroxide conditions, while it was more stable in thermal and photolytic conditions. The described method was linear over a range of 1.0-500 μg/ml for determination of FFB (r= 0.9999). The precision was demonstrated by relative standard deviation (RSD) of intra-day (RSD= 0.56– 0.91) and inter-day studies (RSD= 1.47). The mean recovery was found to be 100.01%. The acid and alkaline degradations of FFB in 1M HCl and 1M NaOH solutions showed an apparent zero-order kinetics with rate constants 0.0736 and 0.0698  min−1 respectively and the peroxide degradation with 5% H2O2 demonstrated an apparent first-order kinetics with rate constant k = 0.0202 per min. The t1/2, t90   values are also determined for all the kinetic studies. The developed method was found to be simple, specific, robust, linear, precise, and accurate for the determination of FFB in pharmaceutical formulations.



Download data is not yet available.


Metrics Loading ...


Fenofibrate, stability-indicating assay, stress study, kinetics of degradation.




How to Cite

Rao KS, N K K, Jena N, Rao M, Patnaik AK. Stability Indicating Liquid Chromatographic Method for the Determination of Fenofibrate and its Application to Kinetic Studies. Scopus Indexed [Internet]. 2013 Feb. 28 [cited 2024 Jun. 16];5(4):1866-74. Available from:



Research Articles


Ahuja SS (2007). Assuring quality of drugs by monitoring impurities. Adv Drug Del Rev 59: 3-11.

Alsante KM, Ando A, Brown R, Ensing J, Hatajik TD, Kong W and Tsuda Y (2007). The role of degradant profiling in active pharmaceutical ingredients and drug products. Adv Drug Deliv Rev 59: 29-37.

Bakshi M and Singh S (2002). Development of validated stability-indicating assay methods-critical review. J Pharm Biomed Anal 28: 1011–1040.

Ceren Y and Nuran O (2004). Electrochemical studies and square-wave voltammetric determination of fenofibrate in pharmaceutical formulations. Anal Bioanal Chem 378: 495-498.

Dhabale PN and Gharge DS (2010). Simultaneous spectrophoto-metric estimation of atorvastatin and fenofibrate in bulk drug and dosage form by using simultaneous equation method. Int J ChemTech Res 2: 325-328.

El-Gindy A, Emara S, Mesbah MK and Hadad GM (2005). Spectrophotometric and liquid chromatographic determination of fenofibrate and vinpocetine and their hydrolysis products. Farmaco 60: 425-438.

FDA, Center for Drug Evaluation and Research (CDER), Center for biologics evaluation and research (CBER). Guidance for Industry. Analytical Procedures and Methods Validation. Rockville, USA, 2000.

Gorog S (2008). Industrial and compendial steroid analysis. J Pharm Biomed Anal 48: 247–253.

Gupta KR, Askarkar SS, Rathod PR and Wadodkar SG (2010). Validated spectrophotometric determination of fenofibrate in formulation. Der Pharmacia Sinica 1: 173-178.

Jain N, Raghuwanshi R and Jain D (2008). Development and validation of RP-HPLC method for simultaneous estimation of atorvastatin calcium and fenofibrate in tablet dosage forms. Indian J Pharm Sci 70: 263–265.

Kadav AA and Vora DN (2008). Stability indicating UPLC method for simultaneous determination of atorvastatin, fenofibrate and their degradation products in tablets. J Pharm Biomed Anal 48: 120-126.

Komsta L and Misztal G (2005). Determination of fenofibrate and gemfibrozil in pharmaceuticals by densitometric and videodensitometric thin-layer chromatography. J AOAC Int 88: 1517-1524.

Korany MA, Hewala II and Abdel-Hay KM (2008). Determination of etofibrate, fenofibrate, and atorvastatin in pharmaceutical preparations and plasma using differential pulse polarographic and square wave voltammetric techniques. J AOAC Int 91: 1051-1058.

Lacroix PM, Dawson BA, Sears RW, Black DB, Cyr TD and Ethier JC (1998). Fenofibrate raw materials: HPLC methods for assay and purity and an NMR method for purity. J Pharmaceut Biomed Anal 18: 383-402.

Maryadele JO (2001). Merck index. 13th ed. Merck Research Lab, 4005. NJ (USA).

Masnatta LD, Cuniberti LA, Rey RH and Werba JP (1996). Determination of bezafibrate, ciprofibrate and fenofibric acid in human plasma by high-performance liquid chromatography. J Chrom Biomed Appl 687: 437-442.

Nagaraj, Vipul K and Rajshree M (2007). Simultaneous quantitative resolution of atorvastatin calcium and fenofibrate in pharmaceutical preparation by using derivative ratio spectrophotometry and chemometric calibrations. Anal Sci 23: 445-451.

Shirkhedkar AA and Surana SJ (2009). Simultaneous densitometric TLC analysis of atorvastatin calcium and fenofibrate in the bulk drug and in pharmaceutical formulations. J Planar Chromatog-Mod TLC 22: 355-360.

Swartz M and Krull I (2005). Analytical method validation for biotechnology proteins, peptides, and antibodies. LC-GC 23: 586–593.

The United States Pharmacopeia. Rockville, MD (2008).

Topic Q1A (R2) Stability testing of new drug substances and products. International Conference on Harmonization (ICH), Geneva, Switzerland 2005.